Latest News about ATAI
Recent news which mentions ATAI
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
March 16, 2024
From Benzinga
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
From Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
February 15, 2024
From Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
February 15, 2024
From Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
From Benzinga
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
From Benzinga
From Benzinga
From InvestorPlace
3 Big New Catalysts for Psychedelics Stocks in 2024
January 08, 2024
From Motley Fool
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
January 07, 2024
From Benzinga
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
January 06, 2024
From Benzinga
Atai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD Treatment
January 04, 2024
From Benzinga
From Benzinga
Psychedelic Stock Gainers And Losers From January 1, 2024
January 01, 2024
From Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
December 27, 2023
From Benzinga
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
December 18, 2023
From Benzinga
MindMed’s stock boosted by positive data in trial of LSD as treatment for anxiety disorder
December 14, 2023
From MarketWatch
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
December 11, 2023
From Benzinga
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
December 05, 2023
From Benzinga
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
November 24, 2023
From Benzinga
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
November 23, 2023
From Benzinga
Insiders Buying Taysha Gene Therapies And 3 Other Stocks Under $2
November 21, 2023
From Benzinga
Atai Life Sciences' Q3 Earnings: Near $20M Burned QoQ, Says Funding 'Sufficient' To Streamline 2026
November 14, 2023
From Benzinga
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
November 12, 2023
From Benzinga
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
November 06, 2023
From Benzinga
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More
October 29, 2023
From Benzinga
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
October 22, 2023
From Benzinga
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
October 16, 2023
From Benzinga
Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More
October 06, 2023
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.